Emerging drugs for endometriosis

Guo SW, Sun-Wei Guo, Sun‐Wei Guo
Expert opinion on emerging drugs · 2008 · vol. 13(4) , pp. 547–571 · doi:10.1517/14728210802548360 · PMID:19046127 · W2163398199
review OA: closed CC0 ⤵ 15 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

This review examined novel therapeutic agents for endometriosis, finding that promising preclinical results have not translated into successful clinical trials due to inadequate understanding of disease mechanisms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Endometriosis is a benign, common gynecological disorder affecting mostly women of reproductive age. It is associated with dysmenorrhea, pelvic pain, and subfertility. The current non-surgical medical treatment is not satisfactory and there is a pressing need for novel therapeutics with better efficacy, tolerability and safety profiles. OBJECTIVE: To investigate the development of new therapies for endometriosis. METHODS: The PubMed database has been extensively searched for all compounds tested preclinically and clinically. RESULTS/CONCLUSION: Besides the three main classes of drugs, i.e., GnRH agonists, progestins, and androgenic agents, there are several classes of compounds that have been tested preclinically and clinically. Surprisingly, a considerable proportion of officially registered Phase II/III clinical trials are listed as completed yet no information on their outcomes is available. Three completed and published Phase II trials found the tested compound disappointing. Another two Phase II clinical trials have been suspended. This apparent gap between the generally promising preclinical findings and the clinical trial outcomes reflects our current woefully inadequate understanding of the mechanisms underlying endometriosis-associated pain and subferitility and recurrence of endometriosis; questions the adequacy and value of animal models of endometriosis that are still in use; highlights the difficulty in developing new therapeutics for endometriosis; and calls for more research in the mechanisms underlying endometriosis-associated pain and subferitility and recurrence of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

MeSH descriptors

Drugs, Investigational Endometriosis Animals Drug Discovery Drugs, Investigational Endometriosis Endometriosis Female Humans Infertility, Female Infertility, Female Infertility, Female Pain Pain Pain Recurrence Treatment Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (16)

Source provenance

europepmc
last seen: 2026-08-30T09:23:35.175841+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:18.065553+00:00
License: CC0 · commercial use OK